![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ACAT1 |
Gene summary for ACAT1 |
![]() |
Gene information | Species | Human | Gene symbol | ACAT1 | Gene ID | 38 |
Gene name | acetyl-CoA acetyltransferase 1 | |
Gene Alias | ACAT | |
Cytomap | 11q22.3 | |
Gene Type | protein-coding | GO ID | GO:0001655 | UniProtAcc | A0A140VJX1 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
38 | ACAT1 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.14e-22 | 6.95e-01 | -0.1954 |
38 | ACAT1 | HTA11_83_2000001011 | Human | Colorectum | SER | 2.44e-03 | 4.90e-01 | -0.1526 |
38 | ACAT1 | HTA11_5212_2000001011 | Human | Colorectum | AD | 6.17e-07 | 7.38e-01 | -0.2061 |
38 | ACAT1 | HTA11_6801_2000001011 | Human | Colorectum | SER | 4.25e-04 | 7.47e-01 | 0.0171 |
38 | ACAT1 | HTA11_7469_2000001011 | Human | Colorectum | AD | 1.26e-02 | 7.21e-01 | -0.0124 |
38 | ACAT1 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 3.93e-04 | 4.42e-01 | 0.294 |
38 | ACAT1 | A015-C-203 | Human | Colorectum | FAP | 4.30e-03 | -9.87e-02 | -0.1294 |
38 | ACAT1 | A002-C-205 | Human | Colorectum | FAP | 6.13e-04 | -1.85e-01 | -0.1236 |
38 | ACAT1 | A015-C-104 | Human | Colorectum | FAP | 6.48e-03 | -8.87e-02 | -0.1899 |
38 | ACAT1 | A002-C-116 | Human | Colorectum | FAP | 4.24e-04 | -1.26e-01 | -0.0452 |
38 | ACAT1 | F034 | Human | Colorectum | FAP | 1.44e-02 | -1.10e-01 | -0.0665 |
38 | ACAT1 | F072B | Human | Colorectum | FAP | 2.21e-02 | -1.55e-01 | 0.257 |
38 | ACAT1 | CRC-1-8810 | Human | Colorectum | CRC | 2.07e-02 | -1.36e-01 | 0.6257 |
38 | ACAT1 | LZE3D | Human | Esophagus | HGIN | 1.55e-02 | 5.31e-01 | 0.0668 |
38 | ACAT1 | LZE4T | Human | Esophagus | ESCC | 2.13e-03 | 1.61e-01 | 0.0811 |
38 | ACAT1 | LZE8T | Human | Esophagus | ESCC | 4.12e-06 | 4.26e-02 | 0.067 |
38 | ACAT1 | LZE20T | Human | Esophagus | ESCC | 5.14e-03 | 1.75e-02 | 0.0662 |
38 | ACAT1 | LZE24T | Human | Esophagus | ESCC | 4.55e-10 | 2.97e-01 | 0.0596 |
38 | ACAT1 | P2T-E | Human | Esophagus | ESCC | 2.89e-13 | 1.57e-01 | 0.1177 |
38 | ACAT1 | P4T-E | Human | Esophagus | ESCC | 1.70e-18 | 6.99e-01 | 0.1323 |
Page: 1 2 3 4 5 6 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003465517 | Oral cavity | OSCC | nucleobase-containing compound catabolic process | 244/7305 | 407/18723 | 5.38e-18 | 5.49e-16 | 244 |
GO:004670015 | Oral cavity | OSCC | heterocycle catabolic process | 254/7305 | 445/18723 | 5.07e-15 | 3.31e-13 | 254 |
GO:004427016 | Oral cavity | OSCC | cellular nitrogen compound catabolic process | 256/7305 | 451/18723 | 9.67e-15 | 5.88e-13 | 256 |
GO:001943915 | Oral cavity | OSCC | aromatic compound catabolic process | 263/7305 | 467/18723 | 1.49e-14 | 8.84e-13 | 263 |
GO:190136115 | Oral cavity | OSCC | organic cyclic compound catabolic process | 272/7305 | 495/18723 | 2.73e-13 | 1.36e-11 | 272 |
GO:003166720 | Oral cavity | OSCC | response to nutrient levels | 245/7305 | 474/18723 | 1.02e-08 | 2.10e-07 | 245 |
GO:004873220 | Oral cavity | OSCC | gland development | 226/7305 | 436/18723 | 2.78e-08 | 5.39e-07 | 226 |
GO:000188918 | Oral cavity | OSCC | liver development | 87/7305 | 147/18723 | 5.54e-07 | 8.08e-06 | 87 |
GO:004259416 | Oral cavity | OSCC | response to starvation | 111/7305 | 197/18723 | 5.68e-07 | 8.19e-06 | 111 |
GO:000675318 | Oral cavity | OSCC | nucleoside phosphate metabolic process | 247/7305 | 497/18723 | 6.28e-07 | 8.96e-06 | 247 |
GO:000911719 | Oral cavity | OSCC | nucleotide metabolic process | 243/7305 | 489/18723 | 7.80e-07 | 1.09e-05 | 243 |
GO:006100818 | Oral cavity | OSCC | hepaticobiliary system development | 88/7305 | 150/18723 | 8.13e-07 | 1.12e-05 | 88 |
GO:001969319 | Oral cavity | OSCC | ribose phosphate metabolic process | 199/7305 | 396/18723 | 2.97e-06 | 3.64e-05 | 199 |
GO:000925919 | Oral cavity | OSCC | ribonucleotide metabolic process | 189/7305 | 385/18723 | 3.18e-05 | 2.87e-04 | 189 |
GO:00442724 | Oral cavity | OSCC | sulfur compound biosynthetic process | 82/7305 | 148/18723 | 3.71e-05 | 3.31e-04 | 82 |
GO:00090627 | Oral cavity | OSCC | fatty acid catabolic process | 59/7305 | 100/18723 | 3.99e-05 | 3.48e-04 | 59 |
GO:00067905 | Oral cavity | OSCC | sulfur compound metabolic process | 168/7305 | 339/18723 | 4.50e-05 | 3.84e-04 | 168 |
GO:007252120 | Oral cavity | OSCC | purine-containing compound metabolic process | 199/7305 | 416/18723 | 1.34e-04 | 9.53e-04 | 199 |
GO:000915020 | Oral cavity | OSCC | purine ribonucleotide metabolic process | 178/7305 | 368/18723 | 1.45e-04 | 1.02e-03 | 178 |
GO:00066317 | Oral cavity | OSCC | fatty acid metabolic process | 186/7305 | 390/18723 | 2.65e-04 | 1.69e-03 | 186 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa01200 | Colorectum | AD | Carbon metabolism | 55/2092 | 115/8465 | 5.53e-08 | 8.42e-07 | 5.37e-07 | 55 |
hsa00620 | Colorectum | AD | Pyruvate metabolism | 28/2092 | 47/8465 | 3.71e-07 | 5.41e-06 | 3.45e-06 | 28 |
hsa00280 | Colorectum | AD | Valine, leucine and isoleucine degradation | 25/2092 | 48/8465 | 3.97e-05 | 3.41e-04 | 2.18e-04 | 25 |
hsa00310 | Colorectum | AD | Lysine degradation | 27/2092 | 63/8465 | 1.17e-03 | 7.75e-03 | 4.94e-03 | 27 |
hsa00071 | Colorectum | AD | Fatty acid degradation | 20/2092 | 43/8465 | 1.50e-03 | 8.69e-03 | 5.54e-03 | 20 |
hsa00630 | Colorectum | AD | Glyoxylate and dicarboxylate metabolism | 14/2092 | 30/8465 | 7.25e-03 | 2.97e-02 | 1.89e-02 | 14 |
hsa012001 | Colorectum | AD | Carbon metabolism | 55/2092 | 115/8465 | 5.53e-08 | 8.42e-07 | 5.37e-07 | 55 |
hsa006201 | Colorectum | AD | Pyruvate metabolism | 28/2092 | 47/8465 | 3.71e-07 | 5.41e-06 | 3.45e-06 | 28 |
hsa002801 | Colorectum | AD | Valine, leucine and isoleucine degradation | 25/2092 | 48/8465 | 3.97e-05 | 3.41e-04 | 2.18e-04 | 25 |
hsa003101 | Colorectum | AD | Lysine degradation | 27/2092 | 63/8465 | 1.17e-03 | 7.75e-03 | 4.94e-03 | 27 |
hsa000711 | Colorectum | AD | Fatty acid degradation | 20/2092 | 43/8465 | 1.50e-03 | 8.69e-03 | 5.54e-03 | 20 |
hsa006301 | Colorectum | AD | Glyoxylate and dicarboxylate metabolism | 14/2092 | 30/8465 | 7.25e-03 | 2.97e-02 | 1.89e-02 | 14 |
hsa006202 | Colorectum | SER | Pyruvate metabolism | 22/1580 | 47/8465 | 9.62e-06 | 1.33e-04 | 9.67e-05 | 22 |
hsa012002 | Colorectum | SER | Carbon metabolism | 40/1580 | 115/8465 | 2.77e-05 | 3.41e-04 | 2.47e-04 | 40 |
hsa000712 | Colorectum | SER | Fatty acid degradation | 15/1580 | 43/8465 | 8.60e-03 | 4.26e-02 | 3.09e-02 | 15 |
hsa006203 | Colorectum | SER | Pyruvate metabolism | 22/1580 | 47/8465 | 9.62e-06 | 1.33e-04 | 9.67e-05 | 22 |
hsa012003 | Colorectum | SER | Carbon metabolism | 40/1580 | 115/8465 | 2.77e-05 | 3.41e-04 | 2.47e-04 | 40 |
hsa000713 | Colorectum | SER | Fatty acid degradation | 15/1580 | 43/8465 | 8.60e-03 | 4.26e-02 | 3.09e-02 | 15 |
hsa006204 | Colorectum | MSS | Pyruvate metabolism | 24/1875 | 47/8465 | 1.25e-05 | 1.35e-04 | 8.27e-05 | 24 |
hsa002802 | Colorectum | MSS | Valine, leucine and isoleucine degradation | 21/1875 | 48/8465 | 6.73e-04 | 4.51e-03 | 2.76e-03 | 21 |
Page: 1 2 3 4 5 6 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ACAT1 | SNV | Missense_Mutation | novel | c.906G>T | p.Lys302Asn | p.K302N | P24752 | protein_coding | tolerated(0.12) | benign(0.005) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
ACAT1 | SNV | Missense_Mutation | c.1130N>C | p.Asn377Thr | p.N377T | P24752 | protein_coding | tolerated(0.07) | possibly_damaging(0.732) | TCGA-AR-A256-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD | |
ACAT1 | SNV | Missense_Mutation | c.104C>T | p.Ser35Leu | p.S35L | P24752 | protein_coding | tolerated(0.11) | benign(0.007) | TCGA-BH-A18P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
ACAT1 | insertion | Frame_Shift_Ins | novel | c.636_637insTGCAGCCTCCGCCTCCTGG | p.Ala213CysfsTer11 | p.A213Cfs*11 | P24752 | protein_coding | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
ACAT1 | SNV | Missense_Mutation | c.1069N>T | p.Ser357Cys | p.S357C | P24752 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
ACAT1 | SNV | Missense_Mutation | novel | c.526N>C | p.Glu176Gln | p.E176Q | P24752 | protein_coding | tolerated(0.52) | benign(0.029) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
ACAT1 | SNV | Missense_Mutation | novel | c.1250N>A | p.Gly417Glu | p.G417E | P24752 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
ACAT1 | SNV | Missense_Mutation | rs777462355 | c.1247N>A | p.Gly416Glu | p.G416E | P24752 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ACAT1 | SNV | Missense_Mutation | rs768448235 | c.1142N>C | p.Val381Ala | p.V381A | P24752 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
ACAT1 | SNV | Missense_Mutation | rs370720208 | c.623N>A | p.Arg208Gln | p.R208Q | P24752 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
38 | ACAT1 | ENZYME | SULFASALAZINE | SULFASALAZINE | ||
38 | ACAT1 | ENZYME | PMID25470667-Compound-K-604 | |||
38 | ACAT1 | ENZYME | ATR-01 | |||
38 | ACAT1 | ENZYME | inhibitor | 381118860 | ||
38 | ACAT1 | ENZYME | SULFASALAZINE | SULFASALAZINE |
Page: 1 |